FDA Focusing Enforcement Efforts on GMP Compliance As Off-Label Prosecutions Wane
This article was originally published in The Gold Sheet
Executive Summary
With recent court decisions largely stripping FDA of its powers to take pharmaceutical manufacturers to court for promoting off-label uses, the agency is shifting its enforcement focus to GMP violations, says attorney.